Thomas E Hutson

List of Publications by Citations

203 papers	34,202 citations	56 h-index	184 g-index
212 ext. papers	38,829 ext. citations	7.8 avg, IF	6.44 L-index

#	Paper	IF	Citations
203	Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. *New England Journal of Medicine*, **2007**, 356, 115-24	59.2	4650
202	Sorafenib in advanced clear-cell renal-cell carcinoma. *New England Journal of Medicine*, **2007**, 356, 125-34	59.2	4006
201	Abiraterone and increased survival in metastatic prostate cancer. *New England Journal of Medicine*, **2011**, 364, 1995-2005	59.2	3019
200	Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. *Lancet, The*, **2008**, 372, 449-56	40	2451
199	Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. *Journal of Clinical Oncology*, **2009**, 27, 3584-90	2.2	1729
198	Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. *New England Journal of Medicine*, **2012**, 366, 707-14	59.2	1697
197	Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. *Lancet, The*, **2011**, 378, 1931-9	40	1406
196	Pazopanib versus sunitinib in metastatic renal-cell carcinoma. *New England Journal of Medicine*, **2013**, 369, 722-31	59.2	1332
195	Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors. *Cancer*, **2010**, 116, 4256-65	6.4	904
194	Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. *Journal of Clinical Oncology*, **2009**, 27, 3312-8	2.2	897
193	RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. *New England Journal of Medicine*, **2012**, 366, 207-15	59.2	838
192	Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. *New England Journal of Medicine*, **2015**, 373, 1814-23	59.2	762
191	Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. *Lancet Oncology, The*, **2016**, 17, 917-927	21.7	580
190	Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. *Lancet Oncology, The*, **2015**, 16, 1473-1482	21.7	575
189	Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. *Nature Medicine*, **2018**, 24, 749-757	50.5	558
188	Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. *Lancet Oncology, The*, **2013**, 14, 552-62	21.7	534
187	Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. *Journal of Clinical Oncology*, **2009**, 27, 1280-9	2.2	404

186	Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy. *Journal of Clinical Oncology*, **2011**, 29, 2432-8	2.2	349
185	Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. *Journal of Clinical Oncology*, **2008**, 26, 3743-8	2.2	346
184	Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial. *Journal of Clinical Oncology*, **2013**, 31, 3791-9	2.2	310
183	Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial. *Lancet Oncology, The*, **2013**, 14, 1287-94	21.7	301
182	Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. *Journal of Clinical Oncology*, **2013**, 31, 1767-74	2.2	295
181	Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. *Journal of Clinical Oncology*, **2014**, 32, 760-7	2.2	290
180	Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. *New England Journal of Medicine*, **2021**, 384, 1289-1300	59.2	263
179	Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. *Journal of Clinical Oncology*, **2010**, 28, 475-80	2.2	245
178	Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. *Journal of Clinical Oncology*, **2012**, 30, 1371-7	2.2	223
177	Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials. *Lancet Oncology, The*, **2012**, 13, 827-37	21.7	212
176	Overall survival in renal-cell carcinoma with pazopanib versus sunitinib. *New England Journal of Medicine*, **2014**, 370, 1769-70	59.2	199
175	A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. *Lancet Oncology, The*, **2011**, 12, 211-4	21.7	186
174	Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies. *Oncologist*, **2008**, 13, 1084-96	5.7	168
173	Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma. *Cancer*, **2008**, 113, 1552-8	6.4	162
172	Pazopanib: a novel multitargeted tyrosine kinase inhibitor. *Current Oncology Reports*, **2007**, 9, 115-9	6.3	155
171	Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer. *Journal of Clinical Oncology*, **2012**, 30, 507-12	2.2	151
170	Targeted therapies for the treatment of metastatic renal cell carcinoma: clinical evidence. *Oncologist*, **2011**, 16 Suppl 2, 14-22	5.7	139
169	Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes. *Journal of Clinical Oncology*, **2011**, 29, 2557-64	2.2	130

168	Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma. *Annals of Oncology*, **2011**, 22, 295-300	10.3	128
167	Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma. *British Journal of Cancer*, **2014**, 111, 1909-16	8.7	125
166	Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy. *Annals of Oncology*, **2010**, 21, 319-324	10.3	109
165	Sunitinib rechallenge in metastatic renal cell carcinoma patients. *Cancer*, **2010**, 116, 5400-6	6.4	106
164	Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer. *Annals of Oncology*, **2012**, 23, 1803-8	10.3	104
163	Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study. *European Journal of Cancer*, **2012**, 48, 333-9	7.5	103
162	Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma. *British Journal of Cancer*, **2013**, 108, 2470-7	8.7	101
161	Independent assessment of lenvatinib plus everolimus in patients with metastatic renal cell carcinoma. *Lancet Oncology, The*, **2016**, 17, e4-5	21.7	86
160	Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial. *British Journal of Cancer*, **2014**, 110, 2821-8	8.7	78
159	Gemcitabine, Cisplatin, and sunitinib for metastatic urothelial carcinoma and as preoperative therapy for muscle-invasive bladder cancer. *Clinical Genitourinary Cancer*, **2013**, 11, 175-81	3.3	74
158	A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC). *Cancer Chemotherapy and Pharmacology*, **2014**, 73, 181-9	3.5	70
157	Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study. *Lancet Oncology, The*, **2020**, 21, 95-104	21.7	70
156	Clinical and immunologic effects of subcutaneously administered interleukin-12 and interferon alfa-2b: phase I trial of patients with metastatic renal cell carcinoma or malignant melanoma. *Journal of Clinical Oncology*, **2004**, 22, 2891-900	2.2	69
155	Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma. *Expert Opinion on Investigational Drugs*, **2008**, 17, 253-61	5.9	68
154	The role of aberrant VHL/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma. *Clinical Cancer Research*, **2013**, 19, 5218-26	12.9	65
153	Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma. *Cancer Chemotherapy and Pharmacology*, **2014**, 74, 739-50	3.5	63
152	Long-term safety of sorafenib in advanced renal cell carcinoma: follow-up of patients from phase III TARGET. *European Journal of Cancer*, **2010**, 46, 2432-40	7.5	62
151	Temporal concurrence of vasculitis and cancer: a report of 12 cases. *Arthritis and Rheumatism*, **2000**, 13, 417-23		62

150	Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma. *British Journal of Cancer*, **2014**, 110, 1125-32	8.7	61
149	Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tasquinimod in Men With Metastatic Castration-Resistant Prostate Cancer. *Journal of Clinical Oncology*, **2016**, 34, 2636-43	2.2	60
148	Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab. *Cancer*, **2010**, 116, 5383-90	6.4	59
147	Treatment of patients with metastatic renal cell cancer: a RAND Appropriateness Panel. *Cancer*, **2006**, 107, 2375-83	6.4	53
146	A phase II study of atezolizumab (atezo) with or without bevacizumab (bev) versus sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC) patients (pts).. *Journal of Clinical Oncology*, **2017**, 35, 431-431	2.2	52
145	Efficacy and safety of everolimus in elderly patients with metastatic renal cell carcinoma: an exploratory analysis of the outcomes of elderly patients in the RECORD-1 Trial. *European Urology*, **2012**, 61, 826-33	10.2	51
144	New treatment options for metastatic renal cell carcinoma. *ESMO Open*, **2017**, 2, e000185	6	49
143	Sequential use of targeted agents in the treatment of renal cell carcinoma. *Critical Reviews in Oncology/Hematology*, **2011**, 77, 48-62	7	48
142	Axitinib for renal cell carcinoma. *Expert Opinion on Investigational Drugs*, **2008**, 17, 741-8	5.9	46
141	IMmotion150: A phase II trial in untreated metastatic renal cell carcinoma (mRCC) patients (pts) of atezolizumab (atezo) and bevacizumab (bev) vs and following atezo or sunitinib (sun).. *Journal of Clinical Oncology*, **2017**, 35, 4505-4505	2.2	45
140	Sequencing of agents for metastatic renal cell carcinoma: can we customize therapy?. *European Urology*, **2012**, 61, 307-16	10.2	43
139	Sorafenib tolerability in elderly patients with advanced renal cell carcinoma: results from a large pooled analysis. *British Journal of Cancer*, **2013**, 108, 311-8	8.7	43
138	Circulating proteins as potential biomarkers of sunitinib and interferon-efficacy in treatment-naïve patients with metastatic renal cell carcinoma. *Cancer Chemotherapy and Pharmacology*, **2014**, 73, 151-61	3.5	42
137	Administration of cisplatin-based chemotherapy for advanced urothelial carcinoma in the community. *Clinical Genitourinary Cancer*, **2012**, 10, 1-5	3.3	42
136	Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis. *BJU International*, **2011**, 108, 1279-83	5.6	42
135	Sunitinib and other targeted therapies for renal cell carcinoma. *British Journal of Cancer*, **2011**, 104, 741-8	8.7	41
134	Characterisation of liver chemistry abnormalities associated with pazopanib monotherapy: a systematic review and meta-analysis of clinical trials in advanced cancer patients. *European Journal of Cancer*, **2015**, 51, 1293-302	7.5	40
133	Axitinib Versus Sorafenib in First-Line Metastatic Renal Cell Carcinoma: Overall Survival From a Randomized Phase III Trial. *Clinical Genitourinary Cancer*, **2017**, 15, 72-76	3.3	38

132	Circulating Tumor Cells in a Phase 3 Study of Docetaxel and Prednisone with or without Lenalidomide in Metastatic Castration-resistant Prostate Cancer. *European Urology*, **2017**, 71, 168-171	10.2	38
131	A randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma. *Annals of Oncology*, **2017**, 28, 2754-2760	10.3	37
130	Two phase 2 trials of the novel Akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor-targeted therapy. *Cancer*, **2012**, 118, 6055-62	6.4	37
129	Sunitinib in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer: a phase 1/2 clinical trial. *Annals of Oncology*, **2012**, 23, 688-694	10.3	37
128	Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma **2016**, 4, 81		37
127	Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial. *Journal of Clinical Oncology*, **2018**, 36, 757-764	2.2	33
126	Rapid analysis of docetaxel in human plasma by tandem mass spectrometry with on-line sample extraction. *Journal of Pharmaceutical and Biomedical Analysis*, **2004**, 36, 125-31	3.5	32
125	Sunitinib in Patients With Metastatic Renal Cell Carcinoma: Clinical Outcome According to International Metastatic Renal Cell Carcinoma Database Consortium Risk Group. *Clinical Genitourinary Cancer*, **2018**, 16, 298-304	3.3	31
124	Predictive and prognostic biomarkers of targeted agents and modern immunotherapy in renal cell carcinoma. *ESMO Open*, **2016**, 1, e000013	6	31
123	Phase I trial of phenoxodiol delivered by continuous intravenous infusion in patients with solid cancer. *Annals of Oncology*, **2006**, 17, 860-5	10.3	31
122	Cytokine therapy: a standard of care for metastatic renal cell carcinoma?. *Clinical Genitourinary Cancer*, **2005**, 4, 181-6	3.3	29
121	Cabozantinib Versus Mitoxantrone-prednisone in Symptomatic Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 3 Trial with a Primary Pain Endpoint. *European Urology*, **2019**, 75, 929-937	10.2	26
120	Efficacy of tivozanib treatment after sorafenib in patients with advanced renal cell carcinoma: crossover of a phase 3 study. *European Journal of Cancer*, **2018**, 94, 87-94	7.5	25
119	Q-TWiST analysis to estimate overall benefit for patients with metastatic renal cell carcinoma treated in a phase III trial of sunitinib vs interferon-*British Journal of Cancer*, **2012**, 106, 1587-90	8.7	25
118	Management of recurrent testicular germ cell tumors. *Oncologist*, **2007**, 12, 51-61	5.7	25
117	Safety and Efficacy of Nivolumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study. *Clinical Genitourinary Cancer*, **2020**, 18, 461-468.e3	3.3	24
116	Hormone refractory prostate cancer: Management and advances. *Cancer Treatment Reviews*, **2006**, 32, 90-100	14.4	24
115	Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: study design and rationale. *Future Oncology*, **2019**, 15, 929-941	3.6	23

114	Safety and efficacy of nivolumab plus ipilimumab (NIVO+IPI) in patients with advanced renal cell carcinoma (aRCC) with brain metastases: Interim analysis of CheckMate 920.. *Journal of Clinical Oncology*, **2019**, 37, 4517-4517	2.2	23
113	First-Line and Sequential Use of Pazopanib Followed by Mammalian Target of Rapamycin Inhibitor Therapy Among Patients With Advanced Renal Cell Carcinoma in a US Community Oncology Setting. *Clinical Genitourinary Cancer*, **2015**, 13, 210-7	3.3	22
112	Association of rash with outcomes in a randomized phase II trial evaluating cetuximab in combination with mitoxantrone plus prednisone after docetaxel for metastatic castration-resistant prostate cancer. *Clinical Genitourinary Cancer*, **2012**, 10, 6-14	3.3	22
111	Evolving role of novel targeted agents in renal cell carcinoma. *Oncology*, **2007**, 21, 1175-80; discussion 1184, 1187, 1190	1.8	21
110	A Phase I/II Trial of BNC105P with Everolimus in Metastatic Renal Cell Carcinoma. *Clinical Cancer Research*, **2015**, 21, 3420-7	12.9	20
109	Abiraterone acetate: a promising drug for the treatment of castration-resistant prostate cancer. *Future Oncology*, **2010**, 6, 665-79	3.6	20
108	Evolving role of pegylated interferons in metastatic renal cell carcinoma. *Expert Review of Anticancer Therapy*, **2003**, 3, 823-9	3.5	20
107	Everolimus in metastatic renal cell carcinoma patients intolerant to previous VEGFr-TKI therapy: a RECORD-1 subgroup analysis. *British Journal of Cancer*, **2012**, 106, 1475-80	8.7	19
106	Prospective Observational Study of Pazopanib in Patients with Advanced Renal Cell Carcinoma (PRINCIPAL Study). *Oncologist*, **2019**, 24, 491-497	5.7	17
105	Ketoconazole retains activity in patients with docetaxel-refractory prostate cancer. *Annals of Oncology*, **2009**, 20, 965-6	10.3	17
104	Novel therapeutics for metastatic renal cell carcinoma. *Cancer*, **2009**, 115, 2361-7	6.4	17
103	Targeted therapy for renal cell carcinoma: a new treatment paradigm. *Baylor University Medical Center Proceedings*, **2007**, 20, 244-8	0.6	16
102	Neoadjuvant therapy followed by prostatectomy for clinically localized prostate cancer. *Cancer*, **2007**, 110, 2628-39	6.4	16
101	Final analysis of COMET-2: Cabozantinib (Cabo) versus mitoxantrone/prednisone (MP) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with moderate to severe pain who were previously treated with docetaxel (D) and abiraterone (A) and/or enzalutamide (E).. *Journal of Clinical Oncology*, **2015**, 33, 141-141	2.2	16
100	A randomized, open-label clinical trial of tasisulam sodium versus paclitaxel as second-line treatment in patients with metastatic melanoma. *Cancer*, **2014**, 120, 2016-24	6.4	15
99	A phase II study of GW786034 using a randomized discontinuation design in patients with locally recurrent or metastatic clear-cell renal cell carcinoma. *Clinical Genitourinary Cancer*, **2006**, 4, 296-8	3.3	15
98	Dosing patterns, toxicity, and outcomes in patients treated with first-line sunitinib for advanced renal cell carcinoma in community-based practices. *Clinical Genitourinary Cancer*, **2014**, 12, 413-21	3.3	14
97	Effectiveness of Best Management Practices with Changing Climate in a Maryland Watershed. *Transactions of the ASABE*, **2017**, 60, 769-782	0.9	13

96	Safety and tolerability of sorafenib in clear-cell renal cell carcinoma: a Phase III overview. *Expert Review of Anticancer Therapy*, **2007**, 7, 1193-202	3.5	13
95	Renal cell carcinoma: diagnosis and treatment, 1994-2003. *Baylor University Medical Center Proceedings*, **2005**, 18, 337-40	0.6	13
94	Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study. *Journal of Clinical Oncology*, **2021**, 39, 3725-3736	2.2	13
93	Integrating cytokines and angiogenic factors and tumour bulk with selected clinical criteria improves determination of prognosis in advanced renal cell carcinoma. *British Journal of Cancer*, **2017**, 117, 478-484	8.7	12
92	Gemcitabine and docetaxel in metastatic, castrate-resistant prostate cancer: results from a phase 2 trial. *Cancer*, **2011**, 117, 752-7	6.4	12
91	New advancements and developments in treatment of renal cell carcinoma: focus on pazopanib. *OncoTargets and Therapy*, **2010**, 3, 147-55	4.4	12
90	Phase I trial of PEG-interferon and recombinant IL-2 in patients with metastatic renal cell carcinoma. *Cancer Chemotherapy and Pharmacology*, **2008**, 62, 347-54	3.5	12
89	Active surveillance of metastatic renal cell carcinoma: Results from a prospective observational study (MaRCC). *Cancer*, **2021**, 127, 2204-2212	6.4	12
88	Everolimus vs. temsirolimus for advanced renal cell carcinoma: use and use of resources in the US Oncology Network. *Clinical Genitourinary Cancer*, **2013**, 11, 115-20	3.3	11
87	Renal cell cancer. *Cancer Journal (Sudbury, Mass)*, **2007**, 13, 282-6	2.2	11
86	New approaches in hormone refractory prostate cancer. *American Journal of Clinical Oncology: Cancer Clinical Trials*, **2006**, 29, 196-201	2.7	11
85	A Single-arm, Multicenter, Phase 2 Study of Lenvatinib Plus Everolimus in Patients with Advanced Non-Clear Cell Renal Cell Carcinoma. *European Urology*, **2021**, 80, 162-170	10.2	11
84	Alteplase for central catheter clearance: 1 mg/mL versus 2 mg/2 mL. *Annals of Pharmacotherapy*, **2004**, 38, 351-2	2.9	10
83	Phase I trial of weekly docetaxel and gemcitabine in patients with refractory malignancies. *Cancer*, **2003**, 97, 170-8	6.4	10
82	The Evolution of Systemic Therapy in Metastatic Renal Cell Carcinoma. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2016**, 35, 113-7	7.1	10
81	Target-specific randomized discontinuation trial design: a novel approach in molecular therapeutics. *Investigational New Drugs*, **2010**, 28, 194-8	4.3	9
80	Novel agents for muscle-invasive and advanced urothelial cancer. *BJU International*, **2008**, 101, 937-43	5.6	9
79	Phase II study of azacitidine to restore responsiveness of prostate cancer to hormonal therapy. *Clinical Genitourinary Cancer*, **2007**, 5, 457-9	3.3	9

78	COMPARZ Post Hoc Analysis: Characterizing Pazopanib Responders With Advanced Renal Cell Carcinoma. *Clinical Genitourinary Cancer*, **2019**, 17, 425-435.e4	3.3	9
77	Outcomes in Patients With Metastatic Renal Cell Carcinoma Who Develop Everolimus-Related Hyperglycemia and Hypercholesterolemia: Combined Subgroup Analyses of the RECORD-1 and REACT Trials. *Clinical Genitourinary Cancer*, **2016**, 14, 406-414	3.3	8
76	Sequential targeted therapy after pazopanib therapy in patients with metastatic renal cell cancer: efficacy and toxicity. *Clinical Genitourinary Cancer*, **2014**, 12, 262-9	3.3	8
75	Difficulty in predicting survival in metastatic renal cancer. *Lancet Oncology, The*, **2012**, 13, 859-60	21.7	8
74	Axitinib versus sorafenib as first-line therapy in patients with metastatic renal cell carcinoma (mRCC).. *Journal of Clinical Oncology*, **2013**, 31, LBA348-LBA348	2.2	8
73	Final Overall Survival Results from a Phase 3 Study to Compare Tivozanib to Sorafenib as Third- or Fourth-line Therapy in Subjects with Metastatic Renal Cell Carcinoma. *European Urology*, **2020**, 78, 783-785	10.2	8
72	Germline Genetic Biomarkers of Sunitinib Efficacy in Advanced Renal Cell Carcinoma: Results From the RENAL EFFECT Trial. *Clinical Genitourinary Cancer*, **2017**, 15, 526-533	3.3	7
71	Experimental therapy for advanced renal cell carcinoma. *Expert Opinion on Investigational Drugs*, **2008**, 17, 1693-702	5.9	7
70	Phase II trial of capecitabine and rHu-interferon-alpha-2a in patients with metastatic renal cell carcinoma, limited efficacy, and moderate toxicity. *Urologic Oncology: Seminars and Original Investigations*, **2007**, 25, 46-52	2.8	7
69	Subgroup analyses of METEOR, a randomized phase 3 trial of cabozantinib versus everolimus in patients (pts) with advanced renal cell carcinoma (RCC).. *Journal of Clinical Oncology*, **2016**, 34, 499-499	2.2	7
68	A phase 3 trial to compare efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of patients with metastatic renal cell carcinoma.. *Journal of Clinical Oncology*, **2018**, 36, TPS706-TPS706	2.2	7
67	TIVO-3: A phase III, randomized, controlled, multicenter, open-label study to compare tivozanib to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC).. *Journal of Clinical Oncology*, **2019**, 37, 541-541	2.2	7
66	Molecularly targeted agents for renal cell carcinoma: the next generation. *Clinical Advances in Hematology and Oncology*, **2010**, 8, 357-60, 361-4	0.6	7
65	Phase II trial of sunitinib for the therapy of progressive metastatic castration-refractory prostate cancer after previous docetaxel chemotherapy. *Clinical Genitourinary Cancer*, **2008**, 6, 134-7	3.3	6
64	Recent advances in the therapy of renal cancer. *Expert Opinion on Biological Therapy*, **2007**, 7, 233-42	5.4	6
63	Abstract A11: Lower baseline levels of plasma hepatocyte growth factor, IL-6, and IL-8 are correlated with greater tumor shrinkage in renal cell carcinoma patients treated with pazopanib **2009**,		6
62	Subgroup analyses of a phase III trial comparing tivozanib hydrochloride versus sorafenib as initial targeted therapy for patients (pts) with metastatic renal cell carcinoma (mRCC).. *Journal of Clinical Oncology*, **2013**, 31, 354-354	2.2	6
61	Treatment-free survival (TFS) after discontinuation of first-line nivolumab (NIVO) plus ipilimumab (IPI) or sunitinib (SUN) in intention-to-treat (ITT) and IMDC favorable-risk patients (pts) with advanced renal cell carcinoma (aRCC) from CheckMate 214.. *Journal of Clinical Oncology*, **2019**, 37, 564-564	2.2	6

60	Management of poor-risk metastatic renal cell carcinoma: current approaches, the role of temsirolimus and future directions. *Future Oncology*, **2016**, 12, 533-49	3.6	6
59	Non-muscle-invasive bladder cancer: An overview of potential new treatment options. *Urologic Oncology: Seminars and Original Investigations*, **2021**, 39, 642-663	2.8	6
58	Long-term Duration of First-Line Axitinib Treatment in Advanced Renal Cell Carcinoma. *Targeted Oncology*, **2017**, 12, 333-340	5	5
57	Angiopoietins and non-vascular endothelial growth factor antiangiogenic targets in advanced renal cell carcinoma. *Cancer Journal (Sudbury, Mass)*, **2013**, 19, 307-10	2.2	5
56	Patient selection for phase II trials. *American Journal of Clinical Oncology: Cancer Clinical Trials*, **2009** , 32, 216-9	2.7	5
55	Current optimal chemotherapy for advanced urothelial cancer. *Expert Review of Anticancer Therapy*, **2008**, 8, 51-61	3.5	5
54	Tivozanib, a highly potent and selective inhibitor of VEGF receptor tyrosine kinases, for the treatment of metastatic renal cell carcinoma. *Future Oncology*, **2020**, 16, 2147-2164	3.6	5
53	Phase I study of a 3-drug regimen of gemcitabine/cisplatin/pemetrexed in patients with metastatic transitional cell carcinoma of the urothelium. *Investigational New Drugs*, **2008**, 26, 151-8	4.3	4
52	Problems with the randomized discontinuation design. *Journal of Clinical Oncology*, **2006**, 24, 4669-70; author reply 4670-1	2.2	4
51	Role of 5a-reductase inhibitors and selective estrogen receptor modulators as potential chemopreventive agents for prostate cancer. *Clinical Prostate Cancer*, **2005**, 3, 211-4		4
50	Targeting growth factor and antiangiogenic pathways in clear-cell renal cell carcinoma: rationale and ongoing trials. *Clinical Genitourinary Cancer*, **2006**, 5 Suppl 1, S31-9	3.3	4
49	Tivozanib vs sorafenib targeted therapy for advanced renal cell carcinoma: Final results of a phase III trial (901) and efficacy results of a 2nd line tivozanib extension study (902).. *Journal of Clinical Oncology*, **2015**, 33, 4557-4557	2.2	4
48	Subgroup analyses and updated overall survival from the phase II trial of lenvatinib (LEN), everolimus (EVE), and LEN+EVE in metastatic renal cell carcinoma (mRCC).. *Journal of Clinical Oncology*, **2016**, 34, 4553-4553	2.2	4
47	The Evolution of Systemic Therapy in Metastatic Renal Cell Carcinoma. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2016**, 36, 113-117	7.1	4
46	Pazopanib in the treatment of renal cell carcinoma. *Clinical Investigation*, **2011**, 1, 75-85		3
45	Novel antiangiogenic agents in the treatment of refractory renal cell carcinoma. *Clinical Genitourinary Cancer*, **2008**, 6 Suppl 1, S29-36	3.3	3
44	Sunitinib (SUTENT) for the treatment of metastatic renal cell carcinoma. *Expert Review of Anticancer Therapy*, **2008**, 8, 1723-1731	3.5	3
43	Phase II study of gemcitabine, cisplatin, and sunitinib (S) in patients with advanced urothelial carcinoma (UC).. *Journal of Clinical Oncology*, **2012**, 30, 282-282	2.2	3

42	A phase III trial to compare efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab vs sunitinib alone in first-line treatment of patients (Pts) with metastatic renal cell carcinoma (RCC).. *Journal of Clinical Oncology*, **2017**, 35, TPS4595-TPS4595	2.2	3
41	Randomized phase II, three-arm trial of lenvatinib (LEN), everolimus (EVE), and LEN+EVE in patients (pts) with metastatic renal cell carcinoma (mRCC).. *Journal of Clinical Oncology*, **2015**, 33, 4506-4506	2.2	3
40	Q-TWiST Analysis of Tivozanib Versus Sorafenib in Patients With Advanced Renal Cell Carcinoma in the TIVO-3 Study. *Clinical Genitourinary Cancer*, **2021**, 19, 468.e1-468.e5	3.3	3
39	Axitinib in metastatic renal cell carcinoma: patient characteristics and treatment patterns in US community oncology centers. *Future Oncology*, **2017**, 13, 1323-1332	3.6	2
38	Systemic therapy and novel agents for metastatic castration resistant prostate cancer. *Update on Cancer Therapeutics*, **2009**, 3, 133-145		2
37	Renal cell carcinoma: what does the future hold?. *BJU International*, **2008**, 102, 5-6	5.6	2
36	Phase I trial of vinorelbine and diphenylhydantoin in patients with refractory carcinoma. *Investigational New Drugs*, **2004**, 22, 277-84	4.3	2
35	Frequency of cisplatin administration in patients presenting with advanced urothelial carcinoma in the community.. *Journal of Clinical Oncology*, **2012**, 30, 285-285	2.2	2
34	A phase Ib clinical trial of the multitargeted kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC).. *Journal of Clinical Oncology*, **2013**, 31, 358-358	2.2	2
33	Sequencing of cabazitaxel and abiraterone acetate following docetaxel in metastatic castration-resistant prostate cancer (mCRPC).. *Journal of Clinical Oncology*, **2013**, 31, 79-79	2.2	2
32	Randomized phase 2 study to assess the safety and efficacy of CRLX101 in combination with bevacizumab in patients (pts.) with metastatic renal cell carcinoma (RCC) versus standard of care (SOC).. *Journal of Clinical Oncology*, **2015**, 33, TPS4579-TPS4579	2.2	2
31	Axitinib treatment among patients with mRCC in a U.S. community oncology setting: A retrospective study of 135 patients.. *Journal of Clinical Oncology*, **2016**, 34, 569-569	2.2	2
30	Tivo-3: A phase 3, randomized, controlled, multi-center, open-label study to compare tivozanib hydrochloride to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC).. *Journal of Clinical Oncology*, **2017**, 35, TPS4600-TPS4600	2.2	2
29	Sequential Therapy in Metastatic Renal Cell Carcinoma. *Journal of Kidney Cancer and VHL*, **2016**, 3, 23-35	1.4	2
28	Time to Resolution of Axitinib-Related Adverse Events After Treatment Interruption in Patients With Advanced Renal Cell Carcinoma. *Clinical Genitourinary Cancer*, **2021**, 19, e306-e312	3.3	2
27	Trial design for metastatic castration-resistant prostate cancer. *Journal of Clinical Oncology*, **2008**, 26, 3647-8; author reply 3648-9	2.2	1
26	Systemic chemotherapy for urothelial cancer. *Clinical Genitourinary Cancer*, **2006**, 5, 34-42	3.3	1
25	Endobronchial Sarcoidosis. *Journal of Bronchology*, **2001**, 8, 211-212		1

24	Professional practice gaps and barriers to optimal care of renal cell carcinoma (RCC) among oncologists in the United States.. *Journal of Clinical Oncology*, **2014**, 32, 404-404	2.2	1
23	Overall survival (OS) in METEOR, a randomized phase 3 trial of cabozantinib (Cabo) versus everolimus (Eve) in patients (pts) with advanced renal cell carcinoma (RCC).. *Journal of Clinical Oncology*, **2016**, 34, 4506-4506	2.2	1
22	The effect of geography and the availability of second-line therapy on overall survival in a one-way crossover design study in renal cell carcinoma.. *Journal of Clinical Oncology*, **2016**, 34, e16120-e16120	2.2	1
21	TIVO-3: Subgroup analysis of progression-free survival of tivozanib compared to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC).. *Journal of Clinical Oncology*, **2019**, 37, 4572-4572	2.2	1
20	Practice challenges affecting optimal care as identifed by US medical oncologists who treat renal cell carcinomas. *Journal of Community and Supportive Oncology*, **2014**, 12, 197-204		1
19	ATLAS study: A randomized double-blind phase 3 study of adjuvant axitinib versus placebo in subjects at high risk of recurrent renal cell carcinoma (RCC).. *Journal of Clinical Oncology*, **2014**, 32, TPS4595-TPS4595	2.2	1
18	Sunitinib (SUTENT) for the treatment of metastatic renal cell carcinoma. *Expert Review of Anticancer Therapy*, **2008**, 8, 1723-31	3.5	1
17	Efficacy and safety data from patients with advanced renal cell cancer treated with tivozanib hydrochloride after progression on sorafenib.. *Journal of Clinical Oncology*, **2013**, 31, 364-364	2.2	1
16	Advanced Non-Clear Cell Kidney Cancer: In Search of Rational Treatment Approaches. *Cancer Journal (Sudbury, Mass)*, **2020**, 26, 441-447	2.2	1
15	Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical Trial. *European Urology*, **2021**, 79, 665-673	10.2	1
14	The implementation of lenvatinib/everolimus or lenvatinib/pembrolizumab combinations in the treatment of metastatic renal cell carcinoma. *Expert Review of Anticancer Therapy*, **2021**, 21, 365-372	3.5	1
13	Everolimus for renal cell carcinoma: predictive factors for response and future directions. *Medical Oncology*, **2009**, 26, 46-53	3.7	
12	Novel treatment options for refractory germ cell tumors. *Update on Cancer Therapeutics*, **2008**, 3, 89-96		
11	Development of novel agents and combinations for renal carcinoma. *Update on Cancer Therapeutics* , **2008**, 3, 97-103		
10	Systemic Therapy for Metastatic Renal Cell Carcinoma: Cytokines **2008**, 367-384		
9	Analysis of an online tool to explore evolving practice patterns in renal cell carcinoma (RCC).. *Journal of Clinical Oncology*, **2018**, 36, 674-674	2.2	
8	A phase I study of BPX-201 vaccine plus AP1903 for chemo-naive metastatic castrate-resistant prostate cancer (mCRPC).. *Journal of Clinical Oncology*, **2014**, 32, TPS3132-TPS3132	2.2	
7	Development of Combination Therapy with Targeted Agents **2015**, 349-375		

List of Publications

6	Association of baseline IL-8 and ferritin with clinical outcome with everolimus and BNC105P in the DisrupTOR-1 trial.. *Journal of Clinical Oncology*, **2015**, 33, 475-475	2.2
5	Sunitinib in patients with metastatic renal cell carcinoma: Clinical outcome according to IMDC risk group.. *Journal of Clinical Oncology*, **2017**, 35, 4584-4584	2.2
4	Interferons and Interleukin-2: Molecular Basis of Activity and Therapeutic Results **2009**, 49-78	
3	Management of Newly Diagnosed Metastatic Disease **2012**, 361-378	
2	Angiopoietins and Other Non-VEGF Antiangiogenic Targets in Advanced Renal Cell Carcinoma **2012** , 135-160	
1	Updated phase I results of a phase I/II trial of BNC105P with everolimus in patients with metastatic renal cell carcinoma (mRCC).. *Journal of Clinical Oncology*, **2013**, 31, 397-397	2.2